Researchers ID oral carcinogen in smokeless tobacco
U.S. scientists have identified the first substance in smokeless tobacco that is a strong oral carcinogen, and are calling upon the federal government to regulate
U.S. scientists have identified the first substance in smokeless tobacco that is a strong oral carcinogen, and are calling upon the federal government to regulate
HuangshanDental.com is pleased to present the next installment of Leaders in Dentistry, a series of interviews with researchers, practitioners, and opinion leaders who are influencing
A simple visual screening tool developed by researchers from three medical colleges in India shows promise for detecting oral premalignancies in a general health setting,
An 11-year-old Pennsylvania boy won a trip to the Little League Baseball World Series for submitting the winning slogan in the Oral Health America’s (OHA)
A group of molecular markers has been identified that can help clinicians determine which patients with low-grade oral premalignant lesions are at high risk for
Allegheny General Hospital (AGH) has been awarded a $1.7 million grant from the National Institutes of Health (NIH) to study gene therapy using ultrasound for
Noncancerous tissue (stroma) surrounding cancers of the throat and cervix play an important role in regulating the spread of cancer cells, according to researchers at
The National Institutes of Health (NIH) has awarded a $2.5 million grant for research aimed at creating artificial salivary glands to treat xerostomia. Xerostomia, or
Vaccines for human papillomavirus (HPV) have shown they can prevent the disease, but many countries do not have the resources for national vaccination programs, according
HuangshanDental.com is pleased to present the next installment of Leaders in Dentistry, a series of interviews with researchers, practitioners, and opinion leaders who are influencing
Actors Michael Douglas and Blythe Danner are partnering with the Oral Cancer Foundation (OCF) on a series of public service announcements (PSAs) that stress the
The U.S. Food and Drug Administration (FDA) has accepted a new drug application (NDA) for cabozantinib as a treatment for patients with medullary thyroid cancer.